merged_alzheimers-treatment-kisunla-donanemab.txt
<other>Reviewing the article to ensure accurate answers based solely on the provided text.</other>
<question_number>1</question_number>
<answer>Safety risks including swelling and bleeding in the brain</answer>
<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for other treatments that could be better</answer>
<question_number>3</question_number>
<answer>No correlation between removal of amyloid plaques and clinical response in individual subjects</answer>
<question_number>4</question_number>
<answer>It may negatively affect the perception of Kisunla's safety, though comparisons are difficult due to differences in patients and other factors</answer>
<question_number>5</question_number>
<answer>The higher price reflects the expectation that patients can stop Kisunla after plaques are cleared, potentially reducing overall costs</answer>
<question_number>6</question_number>
<answer>Emphasis on anti-amyloid drugs might discourage patients from participating in trials for other treatments</answer>
<question_number>7</question_number>
<answer>Patients can stop Kisunla after clearing amyloid plaques, reducing the frequency of infusions compared to Leqembi, which is not stopped</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Participants with intermediate tau levels declined more slowly on donanemab than those with high levels</answer>
<other>Ensured all answers are directly derived from the article text without external input.</other>